Arrowhead Pharmaceuticals
Target the Gene, Silence the Disease
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the company's therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
Industry
Biotechnology
Headquarters
Pasadena, California, United States
Company size
609
Founded
2004
What we do
RNA interference (RNAi)TRiM platform (Targeted RNAi Molecule)Genetic-based disease therapeuticsCardiometabolic diseasesPulmonary diseasesLiver diseaseRare genetic diseases
Interested in Arrowhead Pharmaceuticals ?
Join our talent pool to be considered for future opportunities.